Compare NKSH & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKSH | BNR |
|---|---|---|
| Founded | 1891 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.1M | 252.7M |
| IPO Year | 1995 | 2019 |
| Metric | NKSH | BNR |
|---|---|---|
| Price | $37.10 | $20.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 65.9K | 33.1K |
| Earning Date | 04-23-2026 | 06-05-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | ★ 100.81 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $8,176,000.00 | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.95 | ★ N/A |
| Revenue Growth | ★ 9.39 | N/A |
| 52 Week Low | $24.74 | $2.18 |
| 52 Week High | $40.00 | $41.72 |
| Indicator | NKSH | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 54.25 |
| Support Level | $35.41 | $19.72 |
| Resistance Level | $38.07 | $23.80 |
| Average True Range (ATR) | 0.82 | 1.45 |
| MACD | 0.07 | 0.76 |
| Stochastic Oscillator | 49.81 | 76.52 |
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.